HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
eNrFmE1z2jAQhu/8Co8PvWFhiAO0NpmWJi0zyZSSMO30wgh7CSJGcvTBR399ZSAN6ZihkdHkwAFL3l3tvnq0VnixmqfOArggjEau79VcB2jMEkLvI3d4d1VtuRedSjjDC7w3Tc/z6nXXiVMsROTmo94YMBXez5vrz6DfB+52Kk7IxjOI5Yt5SpLU+4rF9AZn+RwnXDCSOHOQU5ZEbqbk5qkTCsl1FJ0l4w8iwzGEaPdkf3Q2Ott/HqLc2H9YVQL4Nab3hUaBGtmMFedAZRdLuGd8XWh6Eo/8elCrtdpGLogYgGCKx9DHctrnbEESSIo94VSAkZPJMrkFvkhB5k4KjaNZPBdGxvEMrwbw2CsO+qMe7cqVrNaqftMPmo1m0PKDs8DIFd9LVbF49CJQNmrUmufNdhMBRQnEJNd4ldZrfrta8xvnKIlRrIRkczQTKBabn9bjA3BvJjLDMvYZlzi1VEAiui+laMkPh8ejQkmIyFK8LpMqzLEeBq6BYW8h+QruuEZYqnP2j32q0hS9MurhDjCWIs751WWKygOcuRqYJqLLqITV4YqaoVGudlokIE5n9jejxcdCX41TEpvST/NJgZDDQe8w/N6IG5+wgCG3B44fhCZsKU4PpH0BWIo+2zC10GjGE39Ub7fO/SAw3m+/tNoOnFuXirMMkEYVEWUI1KMTVpY9WsDFpp7k+xbK3fRbLMYpHOi4RobE0pJ9ahCtbQp7G247UGj0y+WdqZK+K+Dr283fQtMkif5qwAznNs4IrdtjgS+iwGu8w/Psg1ZkVAISx3r0eqt51mq0zKTOixk0lTIT7xFaLpfeFIuqwDqJ3oSf5Di5eE5NqfRoUj/X1t73hZUmY9t0bSltKfTx9vh9XX1Nt/GxNqRsa717f9fCF/qQXEGJWmyJb43LvcvTo/65r7YWdv8Fguy52fTAWGqO2Gq41Li42yp1uOi60iuuAfFtMiEHrn0O6jJE2yunTiVE+XVTp/IH1GYw4w==
pKnyJkh0Jq4C9qp5